Search Results

Genialis, the RNA-biomarker company, announced a new partnership with the Pancreatic Cancer Action Network to expand the validation of the Genialis™ krasID biomarker in the pancreatic cancer histology.

The Pancreatic Cancer Action Network, the leading nonprofit in the fight against pancreatic cancer, announces Anna Berkenblit, MD, MMSc, a clinical oncologist and drug developer, as its first-ever chief scientific and medical officer.

FibroGen, Inc. (NASDAQ: FGEN) announced graduation and completion of the pamrevlumab experimental arm in the Pancreatic Cancer Action Network’s (PanCAN) Precision PromiseSM Phase 2/3 adaptive platform trial, which evaluates pamrevlumab in combination with the chemotherapy treatments gemcitabine and nab-paclitaxel for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).

In an effort to continue accelerating new treatment options for people with pancreatic cancer, the Pancreatic Cancer Action Network announced Oncolytics Biotech, Inc. as the recipient of its second annual PanCAN Therapeutic Accelerator Award.

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”) is partnering with the Esophageal Cancer Action Network (ECAN) to highlight Esophageal Cancer Awareness Month.

The Pancreatic Cancer Action Network, a leading nonprofit in the fight against pancreatic cancer, proudly announces the addition of four esteemed business leaders, Jay T. Backstrom, MD, MPH, Rich Hume, Eric Park and Mace Rothenberg, MD, to its national board of directors.

The Colorectal Cancer Resource & Action Network (CCRAN) is proud to announce their second annual Pan-Tumor Biomarkers Conference, scheduled to take place virtually on June 20-21, 2024, from 9:30 AM to 5:00 PM ET.

The Pancreatic Cancer Action Network proudly announces the addition of fourteen new members to its Scientific and Medical Advisory Board, as well as the elevation of current SMAB members Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center and Gregory Beatty, MD, PhD to the roles of Chair and Vice Chair, respectively.

RenovoRx, Inc., a biopharmaceutical company focused on the localized treatment of solid tumors, announced it joined Pancreatic Cancer Action Network as a sponsor of the organization’s PurpleStride Silicon Valley event, this past Saturday, April 29, 2023.

Oncolytics Biotech® Inc. announced it has submitted an amendment to GOBLET to initiate a new Phase 1/2 cohort evaluating pelareorep in combination with modified FOLFIRINOX with and without atezolizumab in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma.